Search

Displaying results 4821 - 4830 of 5040 in total
  1. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.

  2. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation.

  3. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  4. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated deficiencies in its production (primarily due

  5. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant

  6. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.

  7. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  8. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.

  9. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  10. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da.